學術產出-期刊論文
文章檢視/開啟
書目匯出
-
題名 Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. 作者 詹銘煥
Weng, Chi-Chang
Chen, Zi-An
Chao, Ko-Ting
Ee, Ting-Wei
Lin, Kun-Ju
Chan, Ming-Huan
Hsiao, Ing-Tsung
Yen, Tzu-Chen
Kung, Mei-Ping貢獻者 神經科學研究所 關鍵詞 Animal cells; Animal models; Biochemistry; Biology and life sciences; Cell biology; Cellular neuroscience; Cellular types; Diagnostic medicine; Diagnostic radiology; Dopaminergics; Experimental organism systems; Histochemistry and cytochemistry; techniques; Imaging techniques; Immunohistochemistry techniques; Immunologic techniques; In vivo imaging; Medicine and health sciences; Model organisms; Mouse models; Movement disorders; Neurochemicals; Neurochemistry; Neurodegenerative diseases; Neuroimaging; Neurology; Neurons; Neuroscience; Parkinson disease; Positron emission tomography; Radiology and imaging; Research and analysis methods; Research Article; Tomography 日期 2017-03 上傳時間 30-八月-2017 16:15:39 (UTC+8) 摘要 18F-9-Fluoropropyl-(+)-dihydrotetrabenazine [18F-FP-(+)-DTBZ] positron emission tomography (PET) has been shown to detect dopaminergic neuron loss associated with Parkinson’s disease (PD) in human and neurotoxin-induced animal models. A polyphenol compound, magnolol, was recently proposed as having a potentially restorative effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- or 6-hydroxydopamine-treated animal models. In this study, 18F-FP-(+)-DTBZ PET was used to determine the therapeutic efficacy of magnolol in an MPTP–PD mouse model that was prepared by giving an intraperitoneally (i.p.) daily dose of 25 mg/kg MPTP to male C57BL/6 mice for 5 consecutive days. Twenty-minute static 18F-FP-(+)-DTBZ PET scans were performed before MPTP treatment and 5 days after the termination of MPTP treatment to set up the baseline control. Half of the MPTP-treated mice then received a daily dose of magnolol (10 mg/kg dissolved in corn oil, i.p.) for 6 days. 18F-FP-(+)-DTBZ PET imaging was performed the day after the final treatment. All 18F-FP-(+)-DTBZ PET images were analysed and the specific uptake ratio (SUr) was calculated. Ex vivo autoradiography (ARG) and corresponding immunohistochemistry (IHC) studies were conducted to confirm the distribution of dopaminergic terminals in the striatum. The striatal SUr ratios of 18F-FP-(+)-DTBZ PET images for the Sham, the MPTP, and the MPTP + Magnolol-treated groups were 1.25 ± 0.05, 0.75 ± 0.06, and 1.00 ± 0.11, respectively (n = 4 for each group). The ex vivo 18F-FP-(+)-DTBZ ARG and IHC results correlated favourably with the PET imaging results. 18F-FP-(+)-DTBZ PET imaging suggested that magnolol post-treatment may reverse the neuronal damage in the MPTP-lesioned PD mice. In vivo imaging of the striatal vesicular monoamine transporter type 2 (VMAT2) distribution using 18F-FP-(+)-DTBZ animal PET is a useful method to evaluate the efficacy of therapeutic drugs i.e., magnolol, for the management of PD. 關聯 PLoS ONE 12(3): e0173503 資料類型 article DOI http://dx.doi.org/10.1371/journal.pone.0173503 dc.contributor 神經科學研究所 zh_TW dc.creator (作者) 詹銘煥 zh_TW dc.creator (作者) Weng, Chi-Chang en_US dc.creator (作者) Chen, Zi-An en_US dc.creator (作者) Chao, Ko-Ting en_US dc.creator (作者) Ee, Ting-Wei en_US dc.creator (作者) Lin, Kun-Ju en_US dc.creator (作者) Chan, Ming-Huan en_US dc.creator (作者) Hsiao, Ing-Tsung en_US dc.creator (作者) Yen, Tzu-Chen en_US dc.creator (作者) Kung, Mei-Ping en_US dc.date (日期) 2017-03 dc.date.accessioned 30-八月-2017 16:15:39 (UTC+8) - dc.date.available 30-八月-2017 16:15:39 (UTC+8) - dc.date.issued (上傳時間) 30-八月-2017 16:15:39 (UTC+8) - dc.identifier.uri (URI) https://ah.lib.nccu.edu.tw/item?item_id=129218 - dc.description.abstract (摘要) 18F-9-Fluoropropyl-(+)-dihydrotetrabenazine [18F-FP-(+)-DTBZ] positron emission tomography (PET) has been shown to detect dopaminergic neuron loss associated with Parkinson’s disease (PD) in human and neurotoxin-induced animal models. A polyphenol compound, magnolol, was recently proposed as having a potentially restorative effect in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- or 6-hydroxydopamine-treated animal models. In this study, 18F-FP-(+)-DTBZ PET was used to determine the therapeutic efficacy of magnolol in an MPTP–PD mouse model that was prepared by giving an intraperitoneally (i.p.) daily dose of 25 mg/kg MPTP to male C57BL/6 mice for 5 consecutive days. Twenty-minute static 18F-FP-(+)-DTBZ PET scans were performed before MPTP treatment and 5 days after the termination of MPTP treatment to set up the baseline control. Half of the MPTP-treated mice then received a daily dose of magnolol (10 mg/kg dissolved in corn oil, i.p.) for 6 days. 18F-FP-(+)-DTBZ PET imaging was performed the day after the final treatment. All 18F-FP-(+)-DTBZ PET images were analysed and the specific uptake ratio (SUr) was calculated. Ex vivo autoradiography (ARG) and corresponding immunohistochemistry (IHC) studies were conducted to confirm the distribution of dopaminergic terminals in the striatum. The striatal SUr ratios of 18F-FP-(+)-DTBZ PET images for the Sham, the MPTP, and the MPTP + Magnolol-treated groups were 1.25 ± 0.05, 0.75 ± 0.06, and 1.00 ± 0.11, respectively (n = 4 for each group). The ex vivo 18F-FP-(+)-DTBZ ARG and IHC results correlated favourably with the PET imaging results. 18F-FP-(+)-DTBZ PET imaging suggested that magnolol post-treatment may reverse the neuronal damage in the MPTP-lesioned PD mice. In vivo imaging of the striatal vesicular monoamine transporter type 2 (VMAT2) distribution using 18F-FP-(+)-DTBZ animal PET is a useful method to evaluate the efficacy of therapeutic drugs i.e., magnolol, for the management of PD. en_US dc.format.extent 222984 bytes - dc.format.mimetype application/pdf - dc.relation (關聯) PLoS ONE 12(3): e0173503 en_US dc.subject (關鍵詞) Animal cells; Animal models; Biochemistry; Biology and life sciences; Cell biology; Cellular neuroscience; Cellular types; Diagnostic medicine; Diagnostic radiology; Dopaminergics; Experimental organism systems; Histochemistry and cytochemistry; techniques; Imaging techniques; Immunohistochemistry techniques; Immunologic techniques; In vivo imaging; Medicine and health sciences; Model organisms; Mouse models; Movement disorders; Neurochemicals; Neurochemistry; Neurodegenerative diseases; Neuroimaging; Neurology; Neurons; Neuroscience; Parkinson disease; Positron emission tomography; Radiology and imaging; Research and analysis methods; Research Article; Tomography en_US dc.title (題名) Quantitative analysis of the therapeutic effect of magnolol on MPTP-induced mouse model of Parkinson’s disease using in vivo 18F-9-fluoropropyl-(+)-dihydrotetrabenazine PET imaging. en_US dc.type (資料類型) article dc.identifier.doi (DOI) 10.1371/journal.pone.0173503 dc.doi.uri (DOI) http://dx.doi.org/10.1371/journal.pone.0173503
